Transverse myelitis associated with systemic lupus erythematosus [3];Mielitis transversa asociada a lupus eritematoso sistémico

Revista de Neurologia

Volumn 45, Issue 9, 2007, Pages 573-575

  Bataller Penafiel E ^a   Alcobendas Maestro, Mónica ^b,d   Flores Torres, I ^c   Esclarin De Ruz A ^b  

^a HOSPITAL MORALES MESEGUER   (Spain)

^b HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL NUESTRA SEÑORA DEL PRADO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE;

AUTOIMMUNE DISEASE; AVASCULAR NECROSIS; CLINICAL FEATURE; DISEASE ASSOCIATION; HUMAN; INCIDENCE; LETTER; MUSCLE WEAKNESS; MYELITIS; RASH; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 37349040729     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4509.2007166     Document Type: Letter

References (23)

1. The American College of Rheumatology nomenclature and definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599-608.
2. Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse myelopathy in systemic lupus erythematosus: as analysis of 14 cases and review of the literature. Ann Rheum Dis 2000; 59: 120-4.
3. Téllez JF, Remes JM, Negrete RO, Dávila L. Longitudinal myelitis associated with systemic lupus erythematosus: clinical features and magnetic resonance imaging of six cases. Lupus 2001; 10: 851-6.
4. Provenzale JM, Barboriak DP, Gaensler EH, Robertson RL, Mercer B. Lupus-related myelitis: serial MR findings. AJNR Am J Neuroradiol 1994; 15: 1911-7.
5. Mok CC, Lau CS, Chan Y, Wong RW. Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome. J Rheumatol 1998; 25: 467-73.
6. Inslicht DV, Stein AB, Pomerantz F, Ragnarsson KT. Three women with lupus transverse myelitis: case report and differential diagnosis. Arch Phys Med Rehabil 1998; 79: 456-9.
7. Theodoridou A, Settas L. Demyelination in the rheumatic diseases. J Neurol Neurosurg Psychiatry 2006; 77: 290-5.
8. Trevisani VF, Castro AA, Neves-Neto JF. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev 2006; 19: CD002265.
9. Chen HC, Lai JH, Juan CJ, Kuo SY, Chen CH, Chang DM. Longitudinal myelitis as an initial manifestation of systemic lupus erythematosus. Am J Med Sci 2004; 327: 105-8.
10. Daniels SL. Pruebas funcionales. técnicas manuales de exploración. 3 ed. México: Interamericana; 1973.
11. Masedo AI, Hanley M, Jensen MP, Ehde D, Cardenas DD. Reliability and validity of a self-report FIM FIM-SR. in person with amputation or spinal cord injury and chronic pain. Am J Phys Med Rehabil 2005; 84: 167-76.
12. Lee KC, Carson L, Kinnin E, Patterson V. The Ashworth Scale: a reliable and reproducible method of measuring spasticity. J Neurol Rehabil 1989; 3: 205-9.
13. Pineda M. Afectación neurológica en las enfermedades reumáticas y vasculitis de la infancia. Rev Neurol 2002; 35: 290-6.
14. Tristano AG. Mielitis transversa aguda como parte del síndrome antifosfolípido catastrófico en un paciente con lupus eritematoso sistémico. Rev Neurol 2004; 19: 774-5.
15. D'Cruz DP, Mellor-Pita S, Joven B, Sanna G, Allanson J, Taylor J, et al. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol 2004; 31: 280-5.
16. Pittock SJ, Lucchinetti CF. Inflammatory transverse myelitis: evolving concepts. Curr Opin Neurol 2006; 19: 362-8.
17. Deodhar AA, Hochenedel T, Bennett RM. Longitudinal involvement of the spinal cord in a patient with lupus related transverse myelitis. J Rheumatol 1999; 26: 446-9.
18. Kimura KY. Systemic lupus erythematosus related transverse myelitis presenting longitudinal involvement of the spinal cord. Intern Med 2002; 41: 156-60.
19. Yazawa S, Kawasaki S, Ohi T, Shiomi K, Sugimoto S, Kawagoe J, et al. Development of severe longitudinal atrophy of thoracic spinal cord following lupus-related myelitis. Intern Med 2001; 40: 353-7.
20. Lavalle C, Pizarro S, Drenkard C, Sánchez J, Alarcón D. Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol 1990; 17: 34-7.
21. Carvalho MR, Sato EI, Tebexreni AS, Heidecher RT, Schenkman S, Neto TL. Effects of supervised cardiovascular training program on exercise tolerance, aerobic capacity, and quality of life in patients with lupus erythematosus. Arthritis Rheum 2005; 53: 838-44.
22. Khanna S, Pal H, Pandey RM, Handa R. The relationship between disease activity and quality of life in systemic lupus erythematosus. Rheumatology Oxford. 2004; 43: 1536-40.
23. Kaplin AI, Deshpande DM, Scott E, Krishnam C, Carmen JS. IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Inves 2005; 115: 2731-41.